Jakub Sikora

Jakub Sikora

Auto-generated profile, based on publicly available information

Jakub Sikora

Research Unit for Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MŽMartina Živná
Martina Živná
HHHelena Hůlková
Helena Hůlková
MMMarie Matignon
Marie Matignon
KHKateřina Hodaňová
Kateřina Hodaňová
PVPetr Vylet'AL
Petr Vylet'AL
SKStanislav Kmoch
Stanislav Kmoch

27 May 2015 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MPMaria Praggastis
Maria Praggastis
BTBrett Tortelli
Brett Tortelli
JZJessie Zhang
Jessie Zhang
HFHideji Fujiwara
Hideji Fujiwara
RSRohini Sidhu
Rohini Sidhu
DODaniel S. Ory
Daniel S. Ory
Niemann-Pick Type C1 (NPC1) disease is a rare neurovisceral, cholesterol–sphingolipid lysosomal storage disorder characterized by ataxia, motor impairment, progressive intellectual decline, and dementia. The most prevalent mutation, NPC1I1061T, encodes a misfolded protein with a reduced half-life caused by ER-associated degradation. Therapies directed at stabilization of the mutant NPC1 protein reduce cholesterol storage in fibroblasts but have not been testedin vivobecause of lack of a suitable animal model. Whereas the prominent features of human NPC1 disease are replicated in the nullNpc1−/−mouse, this model is not amenable to examining proteostatic therapies. The objective of the present study was to develop an NPC1 I1061T knock-in mouse in which to test proteostatic therapies. Compared with theNpc1−/−mouse, thisNpc1tm(I1061T)Dsomodel displays a less severe, delayed form of NPC1 disease with respect to weight loss, decreased motor coordination, Purkinje cell death, lipid storage, and premature death. The murine NPC1I1061Tprotein has a reduced half-lifein vivo, consistent with protein misfolding and rapid ER-associated degradation, and can be stabilized by histone deacetylase inhibition. This novel mouse model faithfully recapitulates human NPC1 disease and provides a powerful tool for preclinical evaluation of therapies targeting NPC1 protein variants with compromised stability.

1 September 2006 in Kidney International
Verified
Journal Article
Closed access
PVP. Vylet'AL
P. Vylet'AL
MKM. Kublová
M. Kublová
MKMarie Hubalek Kalbacova
Marie Hubalek Kalbacova
KHK. Hodaňová
K. Hodaňová
VBV. Barešová
V. Barešová
SKStanislav Kmoch
Stanislav Kmoch

20 April 2016 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
CDCristin Davidson
Cristin Davidson
YFYonatan I. Fishman
Yonatan I. Fishman
IPIstván Puskás
István Puskás
JSJulianna Szemán
Julianna Szemán
TSTamás Sohajda
Tamás Sohajda
KDKostantin Dobrenis
Kostantin Dobrenis
Objective Niemann–Pick type C (NPC) disease is a fatal, neurodegenerative, lysosomal storage disorder characterized by intracellular accumulation of unesterified cholesterol (UC) and other lipids. While its mechanism of action remains unresolved, administration of 2-hydroxypropyl-β-cyclodextrin (HPβCD) has provided the greatest disease amelioration in animal models but is ototoxic. We evaluated other cyclodextrins (CDs) for treatment outcome and chemical interaction with disease-relevant substrates that could pertain to mechanism. Methods NPC disease mice treated for 2 weeks with nine different CDs were evaluated for UC, and GM2 and GM3 ganglioside accumulation using immunohisto/cytochemical and biochemical assays. Auditory brainstem responses were determined in wild-type mice administered CDs. CD complexation with UC, gangliosides, and other lipids was quantified. Results Four HPβCDs varying in degrees of substitution, including one currently in clinical trial, showed equivalent storage reduction, while other CDs showed significant differences in relative ototoxicity and efficacy, with reductions similar for the brain and liver. Importantly, HPγCD and two sulfobutylether-CDs showed efficacy with reduced ototoxicity. Complexation studies showed: incomplete correlation between CD efficacy and UC solubilization; an inverse correlation for ganglioside complexation; substantial interaction with several relevant lipids; and association between undesirable increases of UC storage in Kupffer cells and UC solubilization. Interpretation CDs other than HPβCD identified here may provide disease amelioration without ototoxicity and merit long-term treatment studies. While direct interactions of CD-UC are thought central to the mechanism of correction, the data show that this does not strictly correlate with complexation ability and suggest interactions with other NPC disease-relevant substrates should be considered.

1 April 2005 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
HPH. Pavlů‐Pereira
H. Pavlů‐Pereira
BAB. Asfaw
B. Asfaw
HPH. Poupčtová
H. Poupčtová
JLJ. Ledvinová
J. Ledvinová
JSJ. Sikora
J. Sikora
MEM. Elleder
M. Elleder

1 November 2006 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
MHMartin Hřebíček
Martin Hřebíček
LMLenka Mrázová
Lenka Mrázová
VSVolkan Seyrantepe
Volkan Seyrantepe
SDStéphanie Durand
Stéphanie Durand
NRNicole M. Roslin
Nicole M. Roslin
APAlexey Pshezhetsky
Alexey Pshezhetsky